prikaz prve stranice dokumenta Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
  Preuzmi
PDF 1.52 MB
Znanstveni rad - Izvorni znanstveni rad
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
Pediatric Rheumatology, 20 (2022), 1; 96. https://doi.org/10.1186/s12969-022-00763-x
(Paediatric Rheumatology International Trials Organisation (PRINTO)) van Straalen, Joeri W.; de Roock, Sytze; Giancane, Gabriella; Consolaro, Alessandro; Rygg, Marite; Nordal, Ellen B.; Rubio-Pérez, Nadina; Jelušić, Marija; De Inocencio, Jaime; Vojinovic, Jelena; Wulffraat, Nico M.; Bruijning-Verhagen, Patricia C. J.; Ruperto, Nicolino; Swart, Joost F.

Citirajte ovaj rad

van Straalen, J. W., de Roock, S., Giancane, G., Consolaro, A., Rygg, M., Nordal, E. B. ... Swart, J. F. (2022). Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study. Pediatric Rheumatology, 20. (1). doi: 10.1186/s12969-022-00763-x

van Straalen, Joeri W., et al. "Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study." Pediatric Rheumatology, vol. 20, br. 1, 2022. https://doi.org/10.1186/s12969-022-00763-x

van Straalen, Joeri W., Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio Pérez, et al. "Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study." Pediatric Rheumatology 20, br. 1 (2022). https://doi.org/10.1186/s12969-022-00763-x

van Straalen, J. W., et al. (2022) 'Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study', Pediatric Rheumatology, 20(1). doi: 10.1186/s12969-022-00763-x

van Straalen JW, de Roock S, Giancane G, Consolaro A, Rygg M, Nordal EB, i sur.. Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study. Pediatric Rheumatology [Internet]. 14.11.2022. [pristupljeno 15.04.2024.];20(1). doi: 10.1186/s12969-022-00763-x

J. W. van Straalen, et al., "Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study", Pediatric Rheumatology, vol. 20, br. 1, Studeni 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:509097. [Citirano: 15.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:509097
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
AutorJoeri W. van Straalen
AutorSytze de Roock
AutorGabriella Giancane
AutorAlessandro Consolaro
AutorMarite Rygg
AutorEllen B. Nordal
AutorNadina Rubio-Pérez
AutorMarija Jelušić
AutorJaime De Inocencio
AutorJelena Vojinovic
AutorNico M. Wulffraat
AutorPatricia C. J. Bruijning-Verhagen
AutorNicolino Ruperto
AutorJoost F. Swart
KolaboracijaPaediatric Rheumatology International Trials Organisation (PRINTO)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PEDIJATRIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Pedijatrija
Sažetak (engleski)
Background: Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on patient-reported well-being in non-systemic JIA using real-world data. Methods: Biological-naive patients without a history of uveitis were selected from the international Pharmachild registry. Patients starting ETN were matched to patients starting ADA based on propensity score and outcomes were collected at time of therapy initiation and 3-12 months afterwards. Primary outcome at follow-up was the improvement in Juvenile Arthritis Multidimensional Assessment Report (JAMAR) visual analogue scale (VAS) well-being score from baseline. Secondary outcomes at follow-up were decrease in active joint count, adverse events and uveitis events. Outcomes were analyzed using linear and logistic mixed effects models. Results: Out of 158 eligible patients, 45 ETN starters and 45 ADA starters could be propensity score matched resulting in similar VAS well-being scores at baseline. At follow-up, the median improvement in VAS well-being was 2 (interquartile range (IQR): 0.0 - 4.0) and scores were significantly better (P = 0.01) for ETN starters (median 0.0, IQR: 0.0 - 1.0) compared to ADA starters (median 1.0, IQR: 0.0 - 3.5). The estimated mean difference in VAS well-being improvement from baseline for ETN versus ADA was 0.89 (95% CI: -0.01 - 1.78; P = 0.06). The estimated mean difference in active joint count decrease was -0.36 (95% CI: -1.02 - 0.30; P = 0.28) and odds ratio for adverse events was 0.48 (95% CI: 0.16 -1.44; P = 0.19). One uveitis event was observed in the ETN group. Conclusions: Both ETN and ADA improve well-being in non-systemic JIA. Our data might indicate a trend towards a slightly stronger effect for ETN, but larger studies are needed to confirm this given the lack of statistical significance.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPediatric Rheumatology
Brojčani podacivol. 20, br. 1, 96
e-ISSN1546-0096
DOIhttps://doi.org/10.1186/s12969-022-00763-x
URN:NBNurn:nbn:hr:105:509097
Datum objave publikacije2022-11-14
URL dokumentahttps://ped-rheum.biomedcentral.com/articles/10.1186/s12969-022-00763-x
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-07-12 11:02:55